Aptose Biosciences (APTO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants Soumit Roy - Jones Research Operator Good afternoon. My name is Jonathan and I will be your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Biosciences Inc. (Exact name of Registrant as specified in its Charter) Canada 98-1136802 (State or other jurisdiction o ...

Financial Performance - Aptose reported a net loss of $51.2 million for the year ended December 31, 2023, an increase of $9.4 million compared to a net loss of $41.8 million in 2022[12]. - Cash and cash equivalents decreased to $9.3 million as of December 31, 2023, down from $47.0 million at the end of 2022[10]. - Total shareholders' equity decreased to $(2.9) million as of December 31, 2023, compared to $37.7 million in 2022[10]. Research and Development - Research and development expenses rose to $36.8 million in 2023, up $8.7 million from $28.1 million in 2022, primarily due to increased costs associated with the tuspetinib program[14]. - Tuspetinib achieved a complete response/complete response with partial hematologic recovery (CR/CRh) rate of 36% among patients naive to venetoclax at the recommended Phase 2 dose of 80 mg[5]. - The G3 formulation of luxeptinib demonstrated approximately 10-fold better absorption compared to the original G1 formulation, achieving desired plasma exposure levels[7]. - The company plans to initiate a pilot triplet study of tuspetinib, venetoclax, and a hypomethylating agent in frontline therapy for newly diagnosed AML patients in Summer 2024[8]. Capital and Funding - The company completed a public offering on January 30, 2024, raising approximately $9.7 million from the sale of 5,649,122 common shares at $1.71 per share[3]. - A private placement with Hanmi Pharmaceutical on January 31, 2024, generated $4 million, with shares sold at $1.90 each, an 11% premium over the public offering price[4]. Risks and Uncertainties - The company acknowledges significant risks and uncertainties that could impact future results, including capital acquisition for research and operations[23]. - Early-stage drug development risks include demonstrating efficacy, development time/cost, and regulatory approval processes[23]. - There is a potential risk of new manufacturers failing to produce acceptable GMP batches in sufficient quantities[23]. - Unexpected manufacturing defects are highlighted as a significant risk factor[23]. - The company does not intend to update forward-looking statements unless required by law, indicating a cautious approach to investor communications[24]. - Investors are advised not to overly rely on forward-looking statements due to inherent uncertainties[24]. Administrative Expenses - General and administrative expenses increased to $15.6 million in 2023, up from $14.5 million in 2022, driven by higher salaries and professional fees[17].

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:link ...

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:li ...

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the "Public Offering") of 5,649,122 common shares of the Company (the "Common Shares") and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Com ...

Aptose Biosciences (NASDAQ:APTO) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company’s shares.Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share. That has it expecting gross proceeds of $8.4 million from the stock offering.To go along with this, each share of APTO stock sold in the offering comes with one warrant. These warrants are for the purchase of another share of the company’s stock. The ex ...

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the pricing of an underwritten public offering (the "Public Offering") of 4,912,280 common shares of the Company (the "Common Shares") at a public offering price of US $1.71 per share. Each Common Share will also include a warrant to p ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to t ...